Journal
JOURNAL OF NEUROCHEMISTRY
Volume 137, Issue 2, Pages 142-153Publisher
WILEY
DOI: 10.1111/jnc.13551
Keywords
adenosine; cyclic-AMP; neuroprotection; seizure; urate; uric acid
Categories
Funding
- NIH [HL069846, DK068575, DK079307, DK091190, NS084710]
- DOD [W81XWH-10-1-0623, W81XWH-14-2-0018, W81XWH1110150]
- [NS070003]
- U.S. Department of Defense (DOD) [W81XWH1110150] Funding Source: U.S. Department of Defense (DOD)
Ask authors/readers for more resources
Recently, the topic of traumatic brain injury has gained attention in both the scientific community and lay press. Similarly, there have been exciting developments on multiple fronts in the area of neurochemistry specifically related to purine biology that are relevant to both neuroprotection and neurodegeneration. At the 2105 meeting of the National Neurotrauma Society, a session sponsored by the International Society for Neurochemistry featured three experts in the field of purine biology who discussed new developments that are germane to both the pathomechanisms of secondary injury and development of therapies for traumatic brain injury. This included presentations by Drs. Edwin Jackson on the novel 2,3-cAMP pathway in neuroprotection, Detlev Boison on adenosine in post-traumatic seizures and epilepsy, and Michael Schwarzschild on the potential of urate to treat central nervous system injury. This mini review summarizes the important findings in these three areas and outlines future directions for the development of new purine-related therapies for traumatic brain injury and other forms of central nervous system injury.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available